[Translation] A single-center, randomized, open-label, single-dose, parallel-controlled Phase I clinical study comparing the pharmacokinetic characteristics, safety, and immunogenicity of 14028 injection and dulaglutide injection (Duida®) in healthy subjects
以礼来公司在中国上市的度拉糖肽注射液(度易达®)为对照药品,评价单次皮下注射东莞市东阳光生物药研发有限公司提供的14028注射液在健康成年男性受试者中的药代动力学特点,并比较试验药物与对照药品的药代动力学相似性。
[Translation] Using dulaglutide injection (Duida®) marketed in China by Eli Lilly as the control drug, the pharmacokinetic characteristics of a single subcutaneous injection of 14028 injection provided by Dongguan East Sunshine Biopharmaceutical R&D Co., Ltd. in healthy adult male subjects were evaluated, and the pharmacokinetic similarity of the test drug and the control drug was compared.